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Summary
Background—Antiretroviral therapy (ART) substantially decreases morbidity and mortality 
among people living with HIV. In this study, we describe population-level trends in the adult life 
expectancy (LE), and trends in the residual burden of HIV mortality following the rollout of a 
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public sector ART programme in one of the populations with the most severe HIV epidemics in 
the world.
Methods—Data come from a demographic and HIV surveillance system in northern KwaZulu-
Natal (South Africa), and cover the calendar years 2001 through 2014. We use non-parametric 
survival analysis methods to estimate gains in the population-wide LE at age 15 since the 
introduction of ART, and the shortfall of the population-wide adult LE compared to that of the 
HIV negative population (i.e., the LE deficit). LE gains and deficits are further disaggregated by 
age and cause of death using demographic decomposition methods.
Findings—The dataset contains information on 93,903 adults who jointly contribute 535,428 
person-years of observation to the analyses and 9,992 deaths. Since the rollout of ART in 2004, 
adult LE increased by 15·2 years for men (95%-CI: 12·4-17·8), and 17·2 years for women (95%-
CI: 14·5-20·2). Reductions in pulmonary TB and HIV related mortality account for 79·7% of the 
LE gains among men, and 90·7% among women. For men, 9·5% is the result of a decline in 
external injuries. By 2014, the LE deficit had contracted to 1·2 years for men (95%-CI: -2·9-5·8) 
and to 5·3 years for women (95%-CI: 2·6-7·8). Pulmonary TB and HIV are responsible for 84·9% 
of the LE deficit among men in 2011-'14, and for 80·8% among women.
Interpretation—The burden of HIV on adult mortality in this population is rapidly shrinking, but 
remains sizable for women, despite their better engagement with HIV care services. The recent 
gains in adult life-years lived as well as the current LE deficit are almost exclusively due to 
differences in mortality attributed to HIV and pulmonary TB.
Funding—Wellcome Trust, the Bill and Melinda Gates Foundation, and the National Institutes of 
Health.
Introduction
The rollout of antiretroviral therapy (ART) in populations with generalized epidemics has 
greatly improved the survival of people living with HIV (PLHIV), and that has been 
documented in both clinical cohorts and population-based research.1-7 Many studies report 
on changes in all-cause mortality, but do not quantify how much of the overall mortality 
decline is due to a reduction in HIV associated mortality. In addition, most studies are not in 
a position to estimate the residual burden of HIV on population-level adult mortality. We 
seek to remedy both shortcomings with data from a demographic and HIV surveillance site 
in rural KwaZulu-Natal where HIV status is known for a large portion of the population.
We report on trends in the life expectancy (LE) at age 15, and the adult LE by HIV status. 
LE is one of the most widely used summary measures of mortality and well-suited to 
quantify the effects of ART because it values the prolongation of life in addition to the mere 
elimination of deaths from a particular cause. Other adult mortality measures, including the 
probability of dying in adulthood (45q15) are less sensitive to the shift in the age distribution 
of deaths and may therefore underestimate the mortality reductions prompted by the rollout 
of ART.
Our analyses focus on two quantities of great public health interest, namely the gains in 
adult LE since the introduction of ART, and trends in the LE deficit. The LE deficit is 
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defined as the shortfall of the population-wide LE compared to that of the HIV negative 
population, and quantifies the residual burden of HIV mortality in a population. Further, we 
use demographic decomposition techniques to estimate the contribution of changes in HIV 
and other causes of death (CoD) to recent trends in the adult LE and the adult LE deficit. 
These analyses thus update and extend previous work on adult mortality from the same 
study site.2,8-10 All our estimates are disaggregated by sex, and add a new perspective to the 
literature wherein women are routinely considered to have disproportionally benefited from 
the expansion of treatment.11,12
Methods
Study design and population
Data come from the Africa Centre Demographic Information System (ACDIS) in the 
uMkhanyakude District in northern KwaZulu-Natal, covering 434km2 of predominantly 
rural area with a resident adult population of around 45,000 adults (ages 15 years and 
above).13 The population is characterized by high HIV prevalence (29% among adults aged 
15-49 in 2011),14 high levels of cardiovascular risk factors, and high mortality from external 
injuries.2
The public sector ART programme in the study area enrolled its first patients in August 
2004. By the end of 2006 over a thousand patients were receiving treatment, and by 
mid-2011 an estimated 37% of PLHIV in the study population were on ART. 10,15 More 
detail about the expansion of the treatment programme in South Africa, and changes to the 
ART eligibility criteria is given elsewhere.16
Data collection
Demographic surveillance is conducted through tri-annual household visits, and population-
based HIV testing of resident adults is done annually – since 2003-'04 for men and women 
of reproductive age, and since 2007 for all adults. HIV status information is also obtained 
through record linkage with health facilities providing ART in the area covered by the 
ACDIS.
Individuals contribute person-time to the analyses from their fifteenth birthday or from when 
they move into one of the villages under surveillance, and until they move out, die, or turn 
100 years old. The data extraction from the ACDIS database was done in August 2015, and 
observations were administratively censored at the end of 2014.
In order to allocate person-time to HIV status categories we classify the time prior to the 
first recorded HIV test as HIV status unknown. The time following a positive test remains 
positive until censoring or death. The time following the last negative test is considered 
negative for a duration of five years, after which it is classified as unknown. This procedure 
allows for the estimation of mortality rates among HIV negative individuals, but the 
exposure time is sufficiently short to ensure that elevated mortality among seroconvertors 
does not introduce bias (appendix, pp. 2-3). Time between two HIV negative tests is always 
counted as negative no matter how long the interval between tests.
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Ethical approvals for this study were obtained from the Biomedical Research Ethics 
Committee of the University of KwaZulu-Natal, and the Observational Research Ethics 
Committee of the London School of Hygiene and Tropical Medicine. Verbal informed 
consent was obtained from household representatives for the demographic surveillance, and 
individual written consent for the HIV surveillance. The analyses conducted for this paper 
consisted of secondary analysis of de-identified data. The core ACDIS dataset is publicly 
available through the INDEPTH Network Data Repository 
(INDEPTH.ZA031.CMD2014.v1).
Statistical analysis
We present non-parametric estimates of adult LE by sex, year and HIV status. Adult LE is 
defined as the number of additional years that a survivor to age 15 can expect to live if 
subject to the mortality observed in a specific period (appendix, pp. 4-5). LE estimates are 
computed with continuous-time survival analysis techniques as the area under the Kaplan 
Meier survival curve. Percentile-based confidence bounds are obtained via bootstrapping 
with 1,000 replications.
The discussion below focuses on two quantities: (i) the total adult LE gain since introduction 
of ART, and (ii) the remaining adult LE deficit. The total LE gain is the difference between 
the LE estimates for 2003 and 2014, which represent the calendar year before ART became 
available at local health facilities and the last year with available data. The adult LE deficit 
quantifies the extent to which the overall population LE falls short of the LE of HIV negative 
individuals. In other words, it is a summary measure of the mortality impact of the HIV 
epidemic conditional on the background health profile of its population, and is directly 
affected by HIV epidemic severity and efforts to mitigate its mortality impact (e.g., ART).
Adult LE gains and deficits are disaggregated by age and cause of death using a 
demographic decomposition method first proposed by Arriaga.17 The decomposition of the 
LE gains quantifies the contribution of changes in cause-specific mortality in each age group 
to the overall increase in adult LE from 2000-'03 (the pre-ART period) to 2011-'14. The 
decomposition is done for groups of calendar years because the population is too small for 
an analysis by single year. The same methodology is subsequently used for decomposing the 
LE deficit for two periods (2007-'10 and 2011-'14). Their comparison informs us of changes 
in the age and cause distribution of excess mortality as treatment programs come to 
maturation.
Information on the CoDs comes from verbal autopsy (VA) interviews with relatives of 
deceased individuals. VA interpretation is done with the InSilicoVA tool.18 InSilicoVA uses 
a Bayesian model to estimate the cause-specific mortality fractions (CSMF) at the 
population level, and cause-specific probabilities at the individual level. We separately 
generate estimates for sub-populations defined by two broad age groups (below 60 and 60 or 
older), gender, and HIV status at the time of death.
We then aggregate the individual-level cause-specific probabilities to obtain CSMF estimates 
for five-year age groups. The CoD classification scheme for reporting results distinguishes 
HIV/AIDS, pulmonary tuberculosis (TB), other communicable diseases, malignant 
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neoplasms, cardiovascular disease, other non-communicable diseases, external causes, and 
maternal mortality. We report results for pulmonary TB and HIV separately, but we know 
from prior work that they are often difficult to separate on the basis of a VA interview due to 
the similarity of symptoms and high co-morbidity.19 The online appendix maps the CoD 
classification scheme onto the ICD-10 (pp. 6), and summarizes analyses wherein the CoD 
attribution has been done with the InterVA model (pp. 7).20
Role of the funding source
The funders played no role in study design, in the collection, analysis, or interpretation of 
data, in the writing of this report, or in the decision to submit for publication. The 
corresponding author (GR) had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between 2001 and 2014, a cumulative number of 93,903 adults ever resided in the 
demographic surveillance area. They jointly contribute 535,428 person-years of observation 
time and 9,992 deaths to the analyses (Table 1). Verbal autopsy interviews were completed 
for 9,605 of these deaths. Women contribute 59% of the person-years of exposure to the 
study, and the HIV status is known for around 36% of the total person-years lived. The 
online appendix (pp. 2-3) provides more detail on the HIV status information in the dataset.
The crude death rate decreased from 23·1 (95%-CI: 22·3-23·9) to 13·6 (95%-CI: 13·0-14·2) 
per 1,000 person-years between 2001-'04 and 2011-'14. Because HIV surveillance only 
commenced in 2004, mortality estimates by HIV status before the rollout of ART are not 
available. However, the most pronounced mortality declines took place between ages 20 and 
45, which is an age range where HIV-associated mortality is common.
The mortality rate reductions translate into important gains in adult LE (Figure 1 and pp. 4-5 
in the appendix). Overall adult LE reached its nadir in 2003, the year before the introduction 
of ART. Between 2003 and 2014, adult LE increased by 15·2 years for men (95%-CI: 
12·4-17·8), and 17·2 years for women (95%-CI: 14·5-20·2). These estimates represent 
average increases in the adult LE of 1·38 years per annum for men and 1·58 years for 
women, and are much larger than the LE gains estimated for South Africa as a whole 
(appendix, pp. 8). In 2014, the population-wide adult LE in uMkhanyakude reached 45·9 
(95% CI: 43·7-48·4) and 54·2 (95% CI: 52·2-56·2) years for men and women, respectively.
Adult LE estimates by HIV status can be computed from 2007 onwards; the year that the 
HIV testing eligibility criteria were expanded to all adults. The adult LE for HIV negative 
men and women hovered around 47 years for men and 60 years for women for the entire 
period (Figure 1a). Whereas the adult LE of HIV negatives did not change, the outlook for 
PLHIV improved dramatically. Between 2007 and 2014, the number of years that an adult 
HIV positive person can expect to live increased by 18·4 (95% CI: 7·5-33·8) years for men 
and 20·7 (95% CI: 14·5-29·2) years for women (Figure 1b). By 2014, a 15-year old HIV 
positive man could expect to live for another 30·5 years (95%-CI: 24·4-38·3) at the 
prevailing mortality rates. For women this was 44·1 years (95%-CI: 39·1-52·1). The LE of 
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adults whose HIV status is unknown to the study is marginally higher than that of the 
population as a whole, which suggests that PLHIV are under-represented among those with 
an unknown HIV status (Figure 1c).
The LE estimates reported in Figure 1a are the inputs for computing the LE deficit 
associated with HIV (Figure 1d). In 2007, three years after the introduction of ART at local 
health facilities, this deficit was still 13·8 years (95%-CI: 9·7-18·6) for men and 17·7 years 
(95%-CI: 12·3-23·8) for women. By 2014, the LE deficit reduced to 1·2 (95%-CI: -2·9-5·8) 
and 5·3 (95%-CI: 2·6-7·8) years for men and women, respectively.
Figure 2 provides insight into the age groups and CoDs that have contributed to the LE gains 
since the introduction of ART. CoD contributions aggregated over age are reported in Table 
2. The total LE gain that is decomposed in Figure 2 amounts to 10·6 years for men and 13·7 
years for women, and pertains to the 10-year interval between 2001-'04 and 2011-'14. 
Negative values in these plots indicate that the mortality rates from a particular cause in a 
specific age group increased over time and thus had a negative effect on the LE trend. Their 
contributions are very small. The age groups with the largest contribution to the increase in 
adult LE over this period are 25-29 years for women, and 30-34 years for men.
The decomposition by cause indicates that almost all of the recent gains in adult LE result 
from reductions in mortality ascribed to HIV and pulmonary TB. Among men, these two 
causes alone account for a gain of 8·4 adult life-years, or, 79·7% of the total gain. The gain 
in adult LE ascribed to reductions in pulmonary TB and HIV mortality among women is 
12·8 years, or, 90·7% of the total. The relative contribution of HIV within this group of 
causes is larger for women than for men. Among men, a reduction in the number of deaths 
from external injuries contributes one year to the increase in adult LE in the decade under 
consideration, which corresponds to 9·5% of the total LE gain. All the other CoD groups 
contribute less than one year to the change in the adult life-years lived for both men and 
women.
Figure 3 shifts the focus to the age-groups and CoDs that contribute to the shortfall in the 
population-wide LE compared to the HIV negative population. To elicit changes over time, 
the age-cause decomposition of the LE deficit is done for two periods, which indicates that 
the age profile of the LE deficit is becoming older. This is particularly the case for women, 
for whom the median of the age-group contributions to the LE deficit increased from 34·9 to 
36·3 years between 2007-'10 and 2011-'14.
Pulmonary TB and HIV account for most of the shortfall in the population-wide adult LE in 
both periods (Table 2). Among men, they account for 85·0% of the LE deficit in 2007-'10 
and 84·9% in 2011-'14. Among women, their contributions are 85·5% and 80·8%, 
respectively. Most of the remainder is attributed to other communicable diseases. The 
contributions of non-communicable diseases, external injuries and maternal causes to the LE 
deficit are small.
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Discussion
The introduction of ART in public sector health facilities in KwaZulu-Natal marked the 
starting point for unprecedented population-wide increases in adult LE of 1·38 and 1·58 
years per annum for men and women, respectively. The total gains in adult LE between 2003 
and 2014 amount to 15·2 years for men (95%-CI: 12·4-17·8) and 17·2 years for women 
(95%-CI: 14·5-20·2), and extend earlier estimates for this population.8 In comparison, the 
adult LE in Japan after World War II increased at an average rate of around 0·5 years per 
annum for a total gain of 9·4 years between 1947-'49 and 1965-'69, 21 and is one of the 
nations with the most rapid LE increases on record. The pace of the adult LE increases in 
this population in KwaZulu-Natal has been three times faster, and is almost exclusively 
driven by reductions in HIV related mortality. This conclusion is supported by concomitant 
increases in the adult LE of PLHIV, the lack of a decline in the mortality of HIV negatives, 
and an analysis of changes in the CoD structure. A decline in the deaths ascribed to 
pulmonary TB and HIV alone account for around 79·7 and 90·7% of the total LE gain for 
men and women, respectively. Among men, a decline in mortality from external injuries 
represents an additional 9·5% of the adult LE gain in the decade following the rollout of 
ART.
The LE gains directly attributable to ART are probably even larger than the observed 
increases in adult LE because mortality trends also depend on historical patterns of HIV 
incidence. The HIV epidemic in South Africa only peaked in the late 1990s, and LE would 
have declined for another 10 years if ART were not rolled out in 2004.22 This is an 
important difference with a study from rural Uganda where LE gains of a similar magnitude 
have been registered.6 In the Ugandan case, mortality declines brought about by the rollout 
of ART are reinforced by mortality reductions due to earlier declines in HIV incidence, and 
the LE gain attributable to ART is smaller than the observed increase since ART. 6,23
The mortality reductions in the study population are large, but they did not come about 
immediately. Instead, the benefits of ART gradually unfolded, possibly in accordance with 
lowering ART eligibility thresholds, the availability of more efficacious treatment regimens, 
the rollout to primary healthcare facilities, and improvements in patients' engagement with 
HIV services. A few studies have indeed started to document earlier treatment initiation and 
better patient retention,24,25 and suggest that the early assessments of poor engagement with 
HIV services in generalized epidemics no longer apply.26,27 The gradual progress, however, 
raises the question of why health systems have not been able to capitalize on the benefits of 
highly effective treatment faster; why it has taken over a decade to reduce the burden of HIV 
on adult mortality to its current level. In addition, the residual burden of HIV on adult 
mortality is still not negligible, particularly among women whose adult LE in 2014 is still 
5·3 (95%-CI: 2·6-7·8) years lower than that of HIV negative women. Among men, the LE 
deficit is estimated at 1·2 years and no longer statistically different from zero (95%-CI: 
-2·9-5·8). The decomposition of the LE deficit by cause affirms that pulmonary TB and HIV 
almost exclusively account for the surplus mortality, and an earlier analysis suggests that the 
majority of deaths to PLHIV in this population occur among those who have yet to start 
treatment.9 Pre-treatment mortality among PLHIV is, however, declining rapidly,1 and it will 
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be important to continue monitoring mortality in relation to the cascade of HIV care and 
treatment to further improve the delivery of services.
Estimates for the LE deficit also highlight the dual nature of the gender disparities in HIV-
associated mortality because the burden of HIV on adult mortality remains larger for women 
than for men, despite their more sizable gains in adult life-years to date. Several studies have 
suggested that women disproportionally benefit from the rollout of HIV care and treatment 
services in African populations, as indicated higher HIV testing and ART coverage 
rates,28-30 earlier treatment initiation, and lower attrition and mortality rates on ART.30-33 
These conclusions are supported by our findings, but it is important to understand that the 
disproportionate burden of HIV on women, as quantified by the LE deficit, has not yet been 
fully rectified. We also need to appreciate that gender differences in LE gains and deficits do 
not solely result from differences in HIV services utilisation. Because women's HIV 
prevalence is higher than that of men, women lost more life-years to HIV as the epidemic 
unfolded and, consequently, had more life-years to gain from the expansion of treatment. In 
addition, women are infected at younger ages,34 and have lower mortality from causes 
unrelated to HIV. In the absence of treatment, a female HIV infection resulting in an early 
death will therefore incur a larger loss in life-years than a male HIV death. Conversely, 
preventing a female HIV death will result in a larger gain in life-years.
Another noteworthy gender difference relates to the age profile of HIV-associated mortality. 
As treatment programs matured, the median age of the LE deficit among women increased 
by 1·4 years, which indicates that the burden of HIV is not only declining, but also shifting 
to older ages. We do not currently observe this phenomenon among men, and that suggests 
that they still die in large numbers before or shortly after starting therapy.
The survival of PLHIV into older ages will inevitably complicate the attribution of CoDs 
among PLHIV because comorbidities are common.35,36 More generally, any assessment of 
changes in the CoD structure comes with the caveat that VAs are a relatively crude 
instrument for cause of death assignment and its specificity for identifying AIDS deaths 
remains unknown.37 However, our results indicate that the misclassification of causes is 
limited given that VAs attribute between 80 and 86% of the LE deficit to pulmonary TB and 
HIV, and much of the remainder to other communicable diseases. In other words, there is a 
close correspondence between the VA assigned causes of death and the mortality surplus in 
comparison to the population with a known HIV negatives status.
A final word of caution has to do with the attribution of the mortality gains to ART. Because 
the LE of HIV negative men and women has not changed over the period under observation, 
the LE gains must come from mortality reductions among PLHIV. The rollout ART is the 
most plausible reason for that, but we cannot exclude mortality reductions associated with 
improvements in TB treatment and programmes since TB and HIV are so difficult to 
distinguish. Similarly, PLHIV may benefit in other ways from their engagement with health 
services, but little is known about the existence and magnitude such spill-over effects.
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Research in Context
Evidence before this study
We searched PubMed and Medline in June 2016 for studies on the impact of ART and the 
residual burden of HIV on adult mortality. We did not apply any language or date 
restrictions, and used combinations of the search terms “HIV”, “AIDS”, “life 
expectancy”, “population”, “antiretroviral therapy” and “burden”. Several studies report 
on the life expectancy of HIV positive individuals who started ART, and a number of 
institutions regularly report on mortality estimates that are the result of more complex 
modelling exercises. Two studies, one from Uganda and one from South Africa, provide 
direct nonparametric estimates of population-wide changes in (adult) life expectancy 
following the rollout of antiretroviral therapy in generalized HIV epidemics. The South 
African study is based on the same data source used here, and reported an increase of 
11·3 years (both sexes) in the in the life expectancy at age 15 between 2003, the year 
before ART was rolled out, and 2011.
Added value of this study
We extend the analyses for KwaZulu-Natal to 2014, and document per capita adult life 
expectancy gains of 1·38 years per annum for men and 1·58 years for women, for a total 
gain since ART of 15·2 (95%-CI: 12·4-17·8) and 17·2 years (95%-CI: 14·5-20·2) for men 
and women, respectively. We expand on these findings in two novel ways. First, we 
quantify the residual burden of HIV-associated mortality as the shortfall or deficit of the 
population-wide life expectancy compared to the life expectancy of the HIV negative 
population. Among others, this demonstrates that the remaining burden of HIV has 
become relatively small, especially among men. Among women, the adult life expectancy 
deficit is still 5·3 years (95%-CI: 2·6-7·8). Second, we use verbal autopsy (VA) data and a 
new VA interpretation tool (InSilicoVA) to establish that differences in mortality from 
pulmonary TB and HIV explain most of the recent gains in adult life expectancy as well 
as the remaining life expectancy deficit.
Implications of all the available evidence
Unprecedented increases in adult life expectancy associated with a reduction in HIV-
related mortality underscore the success of the ART programme in this population. The 
burden of HIV mortality remains, however, sizable for women, despite their better 
engagement with HIV care services. Women, who have to date gained more adult life-
years than men, continue to bear the highest burden of HIV mortality, which is a finding 
that adds a new perspective to the literature wherein men are often portrayed as the 
“losers of the ART scale-up.”
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Figure 1. Adult LE trends by sex and HIV status, and the LE deficit (uMkhanyakude, 2001-'14)
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Figure 2. Age and cause-group contributions to the gross LE gains between 2001-'04 and 
2011-'14, by sex (uMkhanyakude)
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Figure 3. Age-cause decomposition of the LE deficit in 2007-'10 and 2011-'14, by sex 
(uMkhanyakude)
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Table 2
The contribution of cause of death groups to the LE gains and deficits (uMkhanyakude, 
2001-'14)
Men Women
Years %a Years %a
LE gains: 2001-'04 to 2001-'14
HIV/AIDS 4·22 39·9 9·20 65·4
Pulmonary TB 4·21 39·8 3·56 25·3
Other CD 0·67 6·4 -0·32 -
Neoplasms 011 10 0·10 0·7
CVD 0·21 20 0·33 2·3
Other NCD 0·15 1·4 0·41 2·9
External 101 9·5 0·35 2·5
Maternal - - 0·12 0·9
LE deficit: 2007-'10
HIV/AIDS 2·73 29·7 6·32 47·4
Pulmonary TB 507 55·3 508 38·1
Other CD 1·16 12·6 0·86 6·4
Neoplasms -0 06 - 009 0·6
CVD -008 - 0·14 1·1
Other NCD -0·18 - 0·68 5·1
External 0·21 2·3 0·10 0·8
Maternal - - 006 0·5
LE deficit: 2011-'14
HIV/AIDS 1·79 27·4 3·92 44·5
Pulmonary TB 3·75 57·5 3·20 36·3
Other CD 0·67 10·3 1·27 14·4
Neoplasms 004 0·6 0·26 2·9
CVD -0·21 - -0 02 -
Other NCD -0·50 - -0·36 -
External 0·27 4·7 003 0·3
Maternal - - 0·13 1·5
Notes:
a
Percent of the sum of positive differences in adult LE.
TB=tuberculosis, CD=communicable diseases, CVD= cardiovascular disease, NCD=non-communicable disease
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